Design and results of pacritinib for myelofibrosis trial (PERSIST-1)

Jean-Jacques Kiladjian

Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.

Share this video  
Myeloproliferative Neoplasms
Pacritinib
PERSIST-1
ASCO 2015
Presentation
2nd June 2015
More from Jean-Jacques Kiladjian
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs
The 5-year update on the COMFORT-II clinical trial of ruxolitinib
What's new in myeloproliferative neoplasms?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals